Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.

Autor: Anne-Sophie Hamy, Lauren Darrigues, Enora Laas, Diane De Croze, Lucian Topciu, Giang-Thanh Lam, Clemence Evrevin, Sonia Rozette, Lucie Laot, Florence Lerebours, Jean-Yves Pierga, Marie Osdoit, Matthieu Faron, Jean-Guillaume Feron, Marick Laé, Fabien Reyal

Publikováno v: PLoS ONE, Vol 15, Iss 6, p e0234191 (2020)

IntroductionThe Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. The objective of this work is to independently evalu

Externí odkaz: https://doaj.org/article/00a331b30e81432888d7d03ba4451387

Abstract P2-16-36: Survival benefit of neoadjuvant chemotherapy versus adjuvant chemotherapy in HER2-positive early breast cancer: A propensity score-weighted analysis

Autor: Jean Guillaume Feron, Audrey Bellesoeur, Beatriz Grandal, Arnaud Bresset, Clemence Evrevin, Fabien Reyal, Sonia Rozette, Eléonore De Guillebon, Anne-Sophie Hamy, Enora Laas, Florence Coussy, Marick Laé, Thomas Gaillard, Jean-Yves Pierga

Publikováno v: Cancer Research. 80:P2-16

INTRODUCTION: Neoadjuvant chemotherapy (NAC) is increasingly being used for locally advanced breast cancers (BCs) or aggressive BC tumors. However, no survival benefit of the neoadjuvant approach over receiving chemotherapy in the adjuvant setting ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::882398311772cd082157f8bad7e9b899
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-36

Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy

Autor: Diane De Croze, Claire Senechal, Sonia Rozette, Isabelle Jardin, Fabien Reyal, Julien Guerin, Guillaume Bataillon, Dominique Stoppa-Lyonnet, Clemence Evrevin, Elise Dumas, Sophie Frank, Florence Coussy, Claire Saule, Marick Laé, Enora Laas, Lucie Laot, Jean-Yves Pierga, Anne-Sophie Hamy, Beatriz Grandal, Etienne Brain

IntroductionFive to 10% of breast cancers (BCs) occur in a genetic predisposition context (mainly BRCA pathogenic variant). Nevertheless, little is known about immune tumor infiltration, response to neoadjuvant chemotherapy (NAC), pathologic complete

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::106ab697585b83fc31ed1a8eb34486b6
https://doi.org/10.1101/2020.09.27.20202515

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy

Autor: Marie Osdoit, Jean-Guillaume Feron, Marick Laé, Jean-Yves Pierga, Florence Lerebours, Clemence Evrevin, Lauren Darrigues, Anne-Sophie Hamy, Fabien Reyal, Lucie Laot, Lucian Topciu, Enora Laas, Diane De Croze, Matthieu Faron, Sonia Rozette, Giang-Thanh Lam

Publikováno v: PLoS ONE
PLoS ONE, Public Library of Science, 2020, 15 (6), pp.e0234191. ⟨10.1371/journal.pone.0234191⟩
PLoS ONE, 2020, 15 (6), pp.e0234191. ⟨10.1371/journal.pone.0234191⟩
PLoS ONE, Vol 15, Iss 6, p e0234191 (2020)

IntroductionThe Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. The objective of this work is to independently evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e99a59ac4d86c59d814679dc4fd656ca
https://www.hal.inserm.fr/inserm-02905473/document

Abstract PS13-10: Impact of BRCA mutation status on immune infiltration, chemosensitivity, and prognosis of breast cancer patients treated with neoadjuvant chemotherapy

Autor: Marick Laé, Lucie Laot, Eric Daoud, Isabelle Jardin, Claire Senechal, Florence Coussy, Clara Sebbag, Sonia Rozette, Nadir Sella, Fabien Reyal, Sophie Franck, Beatriz Grandal, Elise Dumas, Clemence Evrevin, Diane De Croze, Anne-Sophie Hamy, Claire Saule, Dominique Stoppa-Lyonnet, Enora Laas

Publikováno v: Cancer Research. 81:PS13-10

Context: The majority of BRCA mutation carriers diagnosed with breast cancer (BC) are treated with chemotherapy. The effectiveness of standard neoadjuvant chemotherapy (NAC) in BRCA associated BC compared to noncarriers has been poorly explored. Obje

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0da7dc328c74b3ac3607cc229bcf8b13
https://doi.org/10.1158/1538-7445.sabcs20-ps13-10